logo BDSP

Base documentaire


  1. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.

    Article - En anglais

    To assess the venous thrombogenicity of low-estrogen oral contraceptives (those containing <50 mug of estrogen) relative to intermediate-dose (50 mug of estrogen) and high-dose (>50 mug of estrogen) formulations, we conducted a cohort study of oral contraceptive users between the ages of 15 and 44 years in the Michigan Medicaid population.

    These data provide evidence that the dose-response relation between oral contraceptive estrogen and venous thromboembolism extends from 50 to 30 mug of estrogen, the dose range of currently marketed formulations.

    Mots-clés Pascal : Amérique du Nord, Amérique, Contraceptif, Voie orale, Toxicité, Epidémiologie, Facteur risque, Thrombose profonde, Thromboembolie, Posologie, Veine pathologie, Homme, Oestrogène, Etats Unis, Vaisseau sanguin pathologie, Appareil circulatoire pathologie

    Mots-clés Pascal anglais : North America, America, Contraceptive, Oral administration, Toxicity, Epidemiology, Risk factor, Deep vein thrombosis, Thromboembolism, Posology, Venous disease, Human, Estrogen, United States, Vascular disease, Cardiovascular disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 91-0264666

    Code Inist : 002B02U03. Création : 199406.